title: Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized trial.
abstract: BACKGROUND
  We report the results of an open, randomized, multicenter trial that compared the efficacy of aspirin to oral anticoagulants (OA) for the prevention of vascular events in patients with symptomatic stenosis of the middle cerebral artery (MCA).
  
  
  METHODS
  Participants were randomly assigned to receive 300 mg/day of aspirin or a dose of OA (target INR 2-3). The MCA stenosis was demonstrated by conventional angiography or by at least two noninvasive examinations. Patients had either transient ischemic attack or cerebral infarct (CI) attributable to the MCA stenosis within 90 days before inclusion. The primary endpoint was: nonfatal CI, nonfatal acute myocardial infarct, vascular death and major hemorrhage. The patients were followed-up for a minimum of 1 year and a maximum of 3 years.
  
  
  RESULTS
  The study included 28 patients (14 in each treatment group); the average age was 67 +/- 9.9 years. Men constituted 68% of the patients. After a mean follow-up of 23.1 +/- 10.9 months, there were no recurrences of CI in both groups. No endpoint was reported in the aspirin group, but 2 patients in the OA group (14.3%) exhibited vascular events: 1 acute myocardial infarct and 1 intracerebral hemorrhage). However, this difference was not statistically significant (p = 0.48).
  
  
  CONCLUSIONS
  Our study suggests that aspirin is the treatment of choice for the prevention of vascular events in patients with symptomatic MCA stenosis.
authors.affiliation: Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. jmarti@santpau.es
authors.forename: J
authors.initials: J
authors.lastname: Martí-Fàbregas
authors.forename: D
authors.initials: D
authors.lastname: Cocho
authors.forename: J-L
authors.initials: JL
authors.lastname: Martí-Vilalta
authors.forename: I
authors.initials: I
authors.lastname: Gich
authors.forename: R
authors.initials: R
authors.lastname: Belvís
authors.forename: Y
authors.initials: Y
authors.lastname: Bravo
authors.forename: M
authors.initials: M
authors.lastname: Millán
authors.forename: M
authors.initials: M
authors.lastname: Castellanos
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez-Campello
authors.forename: J
authors.initials: J
authors.lastname: Egido
authors.forename: D
authors.initials: D
authors.lastname: Geffner
authors.forename: A
authors.initials: A
authors.lastname: Gil-Núñez
authors.forename: J
authors.initials: J
authors.lastname: Marta
authors.forename: R
authors.initials: R
authors.lastname: Navarro
authors.forename: V
authors.initials: V
authors.lastname: Obach
authors.forename: E
authors.initials: E
authors.lastname: Palomeras
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D002539:Cerebral Arterial Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control*; D003251:Constriction, Pathologic; D003374:Coumarins / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D020768:Middle Cerebral Artery / Q000187:drug effects* / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D003374:Coumarins; D010975:Platelet Aggregation Inhibitors; C030123:coumarin; D001241:Aspirin